Skip to content

Determination of the median effective dose (ED50)of intrathecal bupivacaine for percutaneous nephrolithotomy: a dose-finding study

Determination of the median effective dose (ED50)of intrathecal bupivacaine for percutaneous nephrolithotomy: a dose-finding study

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2100053759
Enrollment
Unknown
Registered
2021-11-29
Start date
2021-12-01
Completion date
Unknown
Last updated
2023-07-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

percutaneous nephrolithotomy

Interventions

Experimental group:Different doses of bupivacaine

Sponsors

Shengjing Hospital of China Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. ASA classification I ~ III; 2. Aged 18 to 75 years; 3. Percutaneous nephrolithotomy under elective spinal anesthesia is planned.

Exclusion criteria

Exclusion criteria: 1. Combined with central nervous system diseases; 2. Coagulation disorders; 3. Abnormal platelet count or functional defect; 4. Have taken aspirin within a week; 5. Infection at the puncture site; 6. History of local anesthetic allergy in the past; 7. History of spinal deformity and trauma; 8. History of severe arrhythmia 9. Severe heart and lung insufficiency; 10. Refuse spinal anesthesia.

Design outcomes

Primary

MeasureTime frame
sensory block level;Supplementary dose of epidural lidocaine;

Secondary

MeasureTime frame
blood pressure;Heart rate;Adverse reaction;Onset time of sensory block;motor function score;

Countries

China

Contacts

Public ContactGao Shan

Shengjing Hospital of China Medical University

2359498742@qq.com+86 18940253302

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026